• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    AN2 Therapeutics, Inc. - Common Stock (NQ: ANTX )

    1.380 +0.020 (+1.47%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about AN2 Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 Next >
    AN2 Therapeutics to Participate at Upcoming Investor Conferences
    From AN2 Therapeutics, Inc.
    Via Business Wire
    AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline
    From AN2 Therapeutics, Inc.
    Via Business Wire
    AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
    From AN2 Therapeutics, Inc.
    Via Business Wire
    Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?
    AN2 Therapeutics stock is down on Friday after ANTX investors learned of the company terminating its EBO-301 Phase 2/3 clinical trial. 
    Via InvestorPlace
    Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From AN2 Therapeutics, Inc.
    Via Business Wire
    AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
    From AN2 Therapeutics, Inc.
    Via Business Wire
    Citizens And 2 Other Penny Stocks Insiders Are Buying
    Via Benzinga
    ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024
    ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    Crude Oil Rises; Blend Labs Shares Jump Following Q2 Results
    Via Benzinga
    Exposures Fossil Fuels
    US Stocks Edge Lower; EchoStar Shares Tumble After Q2 Results
    Via Benzinga
    Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce
    AN2 Therapeutics reported topline results from the Phase 2/3 EBO-301 study of epetraborole in treatment-refractory MAC lung disease. The study showed similar sputum culture conversion rates between... 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    We have all of the biggest pre-market stock movers that traders need to know about on Friday with the latest news breakdowns! 
    Via InvestorPlace
    AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
    From AN2 Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024
    ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023
    ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    Nasdaq Edges Lower; ContextLogic Shares Surge
    U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightly lower on Monday. The Dow traded up 0.52% to 38,873.28 while the NASDAQ fell 0.10% to 15,975.16. The... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
    U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and... 
    Via Benzinga
    US Stocks Mixed; Trimble Issues Weak Outlook
    U.S. stocks traded mixed this morning, with the Dow Jones index falling around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.05% to 38,651.80 while the NASDAQ rose... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Is Infectious Disease-Focused AN2 Therapeutics Stock Sinking Today?
    AN2 Therapeutics pauses Phase 3 enrollment for epetraborole trial in Mycobacterium Avium Complex lung disease. Updates expected in summer 2024. 
    Via Benzinga
    Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session
    U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 45 points on Monday. Shares of monday.com Ltd. (NASDAQ: MNDY) fell sharply in today’s pre-market trading after... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.